Last Updated March 23, 2012

ACTOS ARTICLES AND UPDATES

UPDATES

CREATION OF AN ACTOS MDL

October 26, 2011
It will soon be decided whether or not the Actos cases, which are being filed in courts across the country, would be more effectively handled as a multi-district litigation. The United States Judicial Panel on Multi-District Litigation will hold a hearing on December 1, 2011 to discuss this matter. If the Panel decides to create an Actos MDL, the next decision will be in which court and before which judge the MDL will be placed. Thousands of lawsuits against the Actos manufacturer Takeda Pharmaceuticals are expected to be filed by consumers who developed bladder cancer as a result of taking this popular diabetic medication. Click here to see the Notice of Hearing.

Cindy L. Nations
Attorney at Law

ARTICLES

NEW ADVICE ON RISK OF BLADDER CANCER WITH THE ANTI-DIABETIC DRUG PIOGLITAZONE

July 22, 2011
New Advice on Risk of Bladder Cancer
The review found that there is a small increased risk of bladder cancer associate with pioglitazone use. It is not clear if the risk.

Read the full .PDF article on Advice on Risk of Bladder Cancer from MHRA here.

FDA JOINS FRANCE AND GERMANY WITH ACTOS BLADDER CANCER WARNING BUT STOPS SHORT OF RECALL

In preclinical in vivo studies, bladder cancer was observed in male rats receiving clinical equivalent doses of pioglitazone.  In addition, two clinical studies of Actos (the PROactive study, detailed in The Lancet - Oncology and a liver safety study) showed a high percentage of bladder cancer cases in patients taking Actos.

Read the full .PDF article on FDA joining France and Germany for cancer warnings here

URL: http://drsamgirgis.com/2011/06/15/fda-joins-france-and-germany-with-actos-bladder-cancer-warning-but-stops-short-of-recall/#axzz1Xl7SY6Fq

Read the Lancet article here... http://www.thelancet.com/journals/lancet/article/PIIS0140673605675289/abstract

DEPARTMENT OF HEALTH AND HUMAN SERVICES - SUBMITTAL OF ACTOS / ACTOSPLUS MET FOR LABEL CHANGES

Letter from Dept. of Health & Human Services to Takeda Global Research & Development Center, Inc. concerning label changes to reflect reports that the drug Actos can cause bladder cancer. Read the full letter here...

Top of Page